Grant opportunity for projects with commercial potential

Published by CTSI on January 12, 2017

CTSI has released a new RFA for the Translational Product Development Fund, which supports projects that have the potential to be commercialized, such as projects that may lead to the formation of a start-up company or execution of a license agreement with an established commercial entity. 

About the opportunity:

  • Purpose must be to develop a novel therapeutic compound (i.e., drug, small molecule, or biologic), device, diagnostic, or IT product. 
  • Open to all full-time University of Minnesota faculty at all campuses, and Mayo Clinic Associate Consultant to Consultant investigators from Mayo's Rochester campus. Researchers with joint projects between the two institutions are especially encouraged to apply.
  • Funds up to $50,000 in total direct costs in the first stage of funding and provides a customized project development team (PDT) to help advance projects along the translational development pathway.
  • Projects meeting the initial milestones will be eligible to apply for additional funding through this program. 

Mandatory letters of intent due February 8 (by 5pm).

RFA   FAQs

This is the fourth cycle of the Translational Product Development Fund (TPDF) program, which began in 2014 as a collaborative grant initiative between CTSI and the Mayo Clinic Center for Clinical and Translational Science (CCaTS) in conjunction with the Minnesota Partnership for Biotechnology and Medical Genomics (MNP).

For questions, please contact Jodi Fenlon Rebuffoni, program/project manager, CTSI's Office of Discovery and Translation: 612-626-6945 or fenl0003@umn.edu.

About our blog

The Clinical and Translational Science Institute's blog features news, events, and opportunities, as well as stories about the researchers we support.

Contact CTSI's communications team to share your research-related news.

Find all CTSI blog posts